Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: Implications for anticancer drug screening programs

Cancer Research

Volumn 58, Issue 23, 1998, Pages 5263-5266

  Phillips, Roger M ^a   Pearce, Jennifer ^a   Loadman, Paul M ^a   Bibby, Michael C ^a   Cooper, Patricia A ^a   Swaine, David J ^a   Double, John A ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER MODEL; CHEMOSENSITIVITY; COLON TUMOR; DEVICE; DIAGNOSTIC ERROR; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SCREENING; HOLLOW FIBER MEMBRANE; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; INJECTIONS, SUBCUTANEOUS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; TUMOR CELLS, CULTURED;

EID: 0032401828     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Boyd, M. R. Status of the National Cancer Institute preclinical antitumor drug discovery screen: implications for selection of new agents for clinical trial. In: D. V. De Vita, S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology Update, pp. 1-12. Philadelphia: Lippincott, 1989.
2. Paull, K. D., Shoemaker, R. H., Hodes, L., Monks, A., Scudiero, D. A., Rubinstein, L., Plowman, J., and Boyd, M. R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines-development of mean graph and compare alogrithm. J. Natl. Cancer Inst., 81: 1088-1092, 1989.
3. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J., Jr., and Kohn, K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res., 57: 4285-4300, 1997.
4. Monks, A., Scudiero, D. A., Johnson, G. S., Paull, K. D., and Sausville, E. A. The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets. Anti-Cancer Drug Des., 12: 533-541, 1997.
5. Hendriks, H. R., Burtles, S., Radtke, S., Schultz, R. J., Double, J. A., Sausville, E. A., and Newell, D. R. Cell based screening and pharmacological strategies for the selection of new anticancer agents: a collaboration between the National Cancer Institute (NCI). Cancer Research Campaign (CRC) and EORTC. Ann. Oncol., 9(Suppl. 2): 40, 1998.
6. Anderson, L. F. New drug screen assay uses fewer mice, while cutting costs. J. Natl. Cancer Inst., 87: 1213-1214, 1995.
7. Casciari, J. J., Hollingshead, M. G., Alley, M. C., Mayo, J. G., Malspeis, L., Miyauchi, S., Grever, M. R., and Weinstein, J. N. Growth and chemotherapeutic response of cells in a hollow fiber in vitro solid tumor model. J. Natl. Cancer Inst., 86: 1846-1852, 1994.
8. Hollingshead, M. G., Alley, M. C., Camalier, R. F., Abbott, B. J., Mayo, J. G., Malspeis, L., and Grever, M. R. In vivo cultivation of tumour cells in hollow fibres. Life Sci., 57: 131-141, 1995.
9. Phillips, R. M., Bibby, M. C., and Double, J. A. A critical appraisal of the predictive value of in vitro chemosensitivity assays. J. Natl. Cancer Inst., 82: 1457-1468, 1990.
10. Workman P., Twentyman, P., Balkwill, F., Balmain, A., Chaplin, D., Double, J. A., Embleton, J., Newell, D. R., Raymond, R., Staples, J., Stephens, T., and Wallace, J. United Kingdom co-ordinating committee on cancer research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (Ed. 2). Br. J. Cancer, 77: 1-10, 1998.
11. Shweiki, D., Itin, A., and Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia initiated angiogenesis. Nature (Lond.), 359: 843-845, 1992.
12. Nicholls, G., Clark, B. J., and Brown, J. E. Solid phase extraction and optimised separation of doxorubicin, epirubicin and their metabolites using reversed phase high performance liquid chromatography. J. Pharm. Biomed. Anal., 10: 949-957, 1992.
13. Jain, R. K., Schlenger, K., Höckel, M., and Yuan, F. Quantitative angiogenesis assays: progress and problems. Nat. Med., 3: 1203-1208, 1997.